Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 15/20 | 0.41 |
| ▸ | JAK3 | P52333 | 13/20 | 0.41 |
| ▸ | JAK2 | O60674 | 8/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932667 | 0.87 | JAK1 (0.40) | BRAFJAK1JAK3JAK2CSF1R | |
| SCHEMBL9932010 | 0.83 | BRAF (0.41) | BRAF | |
| SCHEMBL9967963 | 0.81 | BRAF (0.67) | BRAFJAK1JAK3JAK2TYK2 | |
| SCHEMBL9931500 | 0.77 | BRAF (0.47) | BRAF | |
| SCHEMBL11971843 | 0.73 | BRAF (0.48) | BRAF | |
| SCHEMBL3388345 | 0.72 | BRAF (0.43) | BRAFJAK1JAK3JAK2CSF1R | |
| SCHEMBL13007800 | 0.72 | JAK1 (0.53) | JAK1JAK3JAK2CSF1RTYK2 | |
| SCHEMBL9932007 | 0.70 | BRAF (0.38) | BRAF | |
| SCHEMBL8293816 | 0.68 | BRAF (0.48) | BRAF | |
| SCHEMBL15086982 | 0.67 | JAK3 (0.62) | JAK1JAK3JAK2CSF1RTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885JAK1 1189/4885JAK3 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.